CTOR (Citius Oncology) Inventory Turnover: 0.01 (As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.63
! 2 Warning Signs
View Full Analysis

What is Citius Oncology Inventory Turnover?

Citius Oncology CTOR -6.07% 10 Inventory Turnover is 0.01 as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Citius Oncology's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.33 Mil. Citius Oncology's Average Total Inventories for the quarter that ended in Mar. 2026 was $22.65 Mil. Citius Oncology's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.01.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Citius Oncology's Days Inventory for the three months ended in Mar. 2026 was 6,281.97.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Citius Oncology's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 13.59.

Citius Oncology  (NAS:CTOR) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Citius Oncology's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=22.6495/0.329*365 / 4
=6,281.97

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Citius Oncology's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=22.6495 / 1.667
=13.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Citius Oncology Inventory Turnover Related Terms

Citius Oncology Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Citius Oncology's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology Inventory Turnover Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
Inventory Turnover
0.00 0.00 0.00 0.00

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.04 0.01
CTOR
10GF Score
Citius Oncology Inc CTOR
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology Inventory Turnover Calculation

Citius Oncology's Inventory Turnover for the fiscal year that ended in Sep. 2025 is calculated as

Inventory Turnover (A: Sep. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Sep. 2025 ) / ((Total Inventories (A: Sep. 2024 ) + Total Inventories (A: Sep. 2025 )) / count )
=0 / ((8.269 + 22.287) / 2 )
=0 / 15.278
=0.00

Citius Oncology's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover (Q: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Mar. 2026 )) / count )
=0.329 / ((22.639 + 22.66) / 2 )
=0.329 / 22.6495
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.01 mean?
Citius Oncology (CTOR) has a Inventory Turnover of 0.01 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Citius Oncology and its competitors.
Is Citius Oncology's Inventory Turnover too high?
Citius Oncology's current Inventory Turnover is 0.01. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Inventory Turnover compare to INCR and BGM?
Citius Oncology's Inventory Turnover of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Drug Manufacturers company?
A good Inventory Turnover depends on the Drug Manufacturers industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Citius Oncology and its competitors. Citius Oncology's current Inventory Turnover is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Inventory Turnover of 0.01. The current Inventory Turnover is 0.01. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Inventory Turnover is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price